The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer

INTRODUCTION: Performance status (PS) is the only known clinical predictor of outcome in patients with advanced non-small-cell lung cancer (NSCLC), although pharmacogenomic markers may also correlate with outcome. The aim of our study was to correlate clinical and pharmacogenomic measures with overa...

Descripción completa

Detalles Bibliográficos
Autores principales: Karim, Nagla A, Bui, Hai, Pathrose, Peterson, Starnes, Sandra, Patil, Ninad, Shehata, Mahmoud, Mostafa, Ahmed, Rao, MB, Zarzour, Ahmad, Anderson, Marshall
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259862/
https://www.ncbi.nlm.nih.gov/pubmed/25520568
http://dx.doi.org/10.4137/CMO.S18369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259862/
https://www.ncbi.nlm.nih.gov/pubmed/25520568
http://dx.doi.org/10.4137/CMO.S18369

Ejemplares similares